Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.76 |
| ▸ | ESR1 | P03372 | 11/20 | 0.76 |
| ▸ | PKLR | P30613 | 1/20 | 0.59 |
| ▸ | GALNT2 | Q10471 | 1/20 | 0.59 |
| ▸ | GALNT1 | Q10472 | 1/20 | 0.59 |
| ▸ | GALNT3 | Q14435 | 1/20 | 0.59 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 0.59 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 0.59 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 0.59 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26768213 | 0.88 | PKLR (0.79) | ESR2ESR1PKLRGALNT2GALNT1 | |
| SCHEMBL22413028 | 0.84 | ESR2 (0.77) | ESR2ESR1 | |
| SCHEMBL22413393 | 0.83 | ESR2 (0.71) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6828078 | 0.83 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6825648 | 0.83 | ESR2 (0.77) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6830085 | 0.80 | ESR2 (0.68) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6828242 | 0.80 | ESR2 (0.89) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6825403 | 0.80 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6828126 | 0.80 | ESR2 (0.73) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6825266 | 0.79 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177457-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20220177457-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| EP-3937926-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | St. Jude Children's Research Hospital, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113825506-A | Small molecules that bind cyclin-dependent kinase inhibitor 1B (P27KIP1) | 圣祖德儿童研究医院 | 2021-12-21 | — | — | CN | disclosed |
| WO-2020186110-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020186110-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177457-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | CDK7, CDK2, CCNI | ESR2 3596/4885ESR1 2562/4885PKLR 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.